70,000 Shares in Innoviva, Inc. $INVA Purchased by Chase Investment Counsel Corp
Chase Investment Counsel Corp has acquired 70,000 shares of Innoviva, Inc. (NASDAQ:INVA) for approximately $1.59 million, representing a new stake of about 0.09% in the company. Institutional ownership in Innoviva remains high at 99.12%, with firms like Vanguard Group and Arrowstreet Capital also increasing their positions. Innoviva has a "Hold" consensus rating from analysts with an average price target of $34.75, despite mixed recent recommendations and a current trading price of around $21.19.
Innoviva’s Earnings Swing And Buyback Might Change The Case For Investing In Innoviva (INVA)
Innoviva (INVA) reported mixed Q2 2026 results with increased revenue but a net loss, contrasting with positive six-month figures. The company also completed a share buyback, signaling a focus on capital returns despite short-term earnings volatility. Investors are encouraged to consider long-term profitability and the impact of the buyback against recent index removals.
Innoviva’s Earnings Swing And Buyback Might Change The Case For Investing In Innoviva (INVA)
Innoviva (INVA) recently reported a Q2 2026 net loss of US$83.42 million despite increased revenue, alongside completing a US$66.40 million share buyback. While the quarterly loss introduces volatility, the company's six-month figures show overall revenue and net income growth, suggesting a complex investment narrative involving historical profitability, low earnings multiples, and capital returns. The article suggests investors consider these factors along with differing fair value estimates and potential risks related to earnings quality.
Bank of America Corp DE Has $37.75 Million Stake in Innoviva, Inc. $INVA
Bank of America Corp DE increased its stake in Innoviva, Inc. (NASDAQ:INVA) by 6.6% in the first quarter, now owning 1,619,994 shares valued at approximately $37.75 million. Institutional investors and hedge funds collectively own 99.12% of Innoviva, and the stock currently has an average "Hold" rating from analysts with an average target price of $34.75. Innoviva is a royalty-focused life sciences company specializing in biopharmaceutical products, particularly inhaled respiratory therapies.
Three Innoviva therapies named finalists for Prix Galien award
Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., announced that three of its infectious disease therapies—XACDURO, ZEVTERA, and NUZOLVENCE—have been named finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This marks the third consecutive year an Innoviva product has been recognized, highlighting advancements in treatments for severe bacterial infections and drug-resistant gonorrhea. The winners will be announced on October 29, 2026.
How (INVA) Movements Inform Risk Allocation Models
This article analyzes Innoviva Inc. (NASDAQ: INVA) using AI models, identifying divergent sentiment across time horizons and suggesting choppy market conditions. It provides specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for support and resistance levels. The report highlights elevated downside risk due to the absence of long-term support signals.
Innoviva stock price target reiterated at $46 by H.C. Wainwright
H.C. Wainwright reiterated a Buy rating and a $46 price target for Innoviva (NASDAQ:INVA) after the company surpassed second-quarter revenue forecasts. Despite a reported net loss of $108 million due to investment value changes, the firm raised its full-year 2026 revenue forecast while maintaining a positive outlook, citing strong growth in its Specialty Therapeutics division and an undervalued stock according to InvestingPro analysis. Innoviva has also recently announced strategic developments, including a new subsidiary, Nortiva Bio, and an international distribution agreement for its drug XACDURO.
Does Innoviva’s Q2 Loss and Buyback-Fueled EPS Shift Change The Bull Case For INVA?
Innoviva, Inc. reported a Q2 net loss of US$83.42 million despite increased revenue, contrasting with a strong first half. The company also completed a US$66.40 million share buyback, retiring 4.12% of its shares. This mixed financial picture, combining lumpy earnings with shareholder-friendly actions, creates a volatile investment narrative, with market sentiment influenced by both recent losses and capital returns.
Innoviva stock price target reiterated at $46 by H.C. Wainwright
H.C. Wainwright has reiterated a Buy rating and a $46 price target for Innoviva, Inc. (NASDAQ:INVA) following the company's Q2 2026 financial results. Innoviva's Q2 revenue beat forecasts, leading H.C. Wainwright to raise its full-year 2026 revenue outlook, though it lowered its 2026 EPS forecast due to investment fair value changes. The company shows positive momentum with strong revenue growth and a profitable outlook despite a quarterly net loss.
Innoviva, Inc. (INVA) Stock Forecasts
Argus has lowered its target price for Innoviva Inc. (INVA) to $23.00, according to a report published on August 5, 2026. Innoviva Inc. is described as a company holding a portfolio of royalties in healthcare assets, including a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. The current price of INVA stock is $20.68.
Innoviva stock price target reiterated at $46 by H.C. Wainwright
H.C. Wainwright reiterated a Buy rating and $46 price target for Innoviva (NASDAQ:INVA) after the company reported strong second-quarter 2026 revenue, exceeding forecasts. Despite a net loss primarily due to fair value changes in investments, the company remains profitable over the last twelve months and holds more cash than debt. Innoviva has also made strategic moves including forming a new subsidiary, Nortiva Bio, and entering into an exclusive distribution agreement for its drug XACDURO.
Does Innoviva’s Q2 Loss and Buyback-Fuled EPS Shift Change The Bull Case For INVA?
Innoviva, Inc. reported a Q2 2026 net loss of US$83.42 million despite increased revenue, leading to a loss per share of US$1.14 from continuing operations. This quarterly loss contrasts with strong first-half net income, creating a volatile earnings picture. The company's recent US$66.40 million share buyback program, which retired 4.12% of shares, aims to return capital to shareholders amidst these fluctuating results and shifting market sentiment.
Innoviva (INVA) Stock Can Revenue Growth Offset A Sharp Profit Reversal
Innoviva (INVA) stock saw a 2.9% increase despite a significant Q2 2026 profit reversal, swinging from a profit of US$63.7 million to a loss of US$83.4 million. The company's revenue, however, grew by 19% to US$119.6 million, driven by its Specialty Therapeutics portfolio and royalty base. Investors are weighing this revenue growth against the sharp earnings decline to determine if the stock is a bargain or a value trap.
Innoviva Inc (INVA) Stock News Today
This article provides current stock information for Innoviva Inc (INVA), including its stock price, market cap, and P/E TTM. It indicates that further news, earnings reports, analyst ratings, and key developments are anticipated to be published soon on the platform. The page primarily serves as a placeholder for future updates regarding the company's stock performance and related news.
How Innoviva’s Q2 Loss and Aggressive Buybacks Could Reshape Capital Allocation for INVA Investors
Innoviva, Inc. reported mixed Q2 2026 results with increased revenue but a swing from net income to a significant net loss, while also completing a substantial share repurchase. This financial performance and capital allocation strategy may prompt investors to re-evaluate the company's investment narrative, especially given ongoing concerns about earnings quality and potential overvaluation despite management's confidence in buybacks. The article encourages investors to analyze various perspectives and fundamental data to form their own convictions about Innoviva's future.
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
Innoviva, Inc. (NASDAQ: INVA) announced strong second-quarter 2026 financial results, driven by robust performance from its royalty portfolio and significant growth in Innoviva Specialty Therapeutics (IST) net product sales. The company achieved 19% year-on-year total revenue growth to $119.6 million and saw IST U.S. net product sales increase by 26%, with a target of at least $150 million for 2026. Innoviva also highlighted key strategic advancements, including a licensing agreement for XACDURO in emerging markets and the launch of Nortiva Bio, a wholly-owned subsidiary focused on novel long-acting oral drug delivery.
Innoviva (INVA) Q2 Earnings and Revenues Top Estimates
Innoviva (INVA) reported Q2 earnings of $0.59 per share, exceeding the Zacks Consensus Estimate of $0.56, and revenues of $119.59 million, also surpassing estimates by 5.63%. Despite outperforming estimates four times over the past year, the stock currently holds a Zacks Rank #5 (Strong Sell) due to an unfavorable trend in estimate revisions. The company's shares have risen 4.4% year-to-date, underperforming the S&P 500's 13% gain.
Earnings Flash (INVA) Innoviva, Inc. Reports Q2 Revenue $119.6M, vs. FactSet Est of $111.0M
Innoviva, Inc. reported its Q2 revenue of $119.6 million, surpassing the FactSet estimate of $111.0 million. The company, a diversified holding company with a focus on healthcare assets and royalties from respiratory products, also announced an update on its equity buyback plan. Innoviva's product portfolio includes treatments for septic shock, complicated intra-abdominal infections, and hospital-acquired pneumonias.
First Trust Advisors LP Grows Stock Holdings in Innoviva, Inc. $INVA
First Trust Advisors LP significantly increased its stake in Innoviva, Inc. by 134.6% in Q1, now holding 278,340 shares valued at approximately $6.5 million. Other institutional investors also adjusted their holdings, with overall institutional ownership at 99.12%. Innoviva's Q1 EPS beat analyst estimates, while revenue slightly missed, and analysts currently rate the stock a "Moderate Buy" with an average price target of $36.20.
Innoviva, Inc. $INVA Shares Sold by Healthcare of Ontario Pension Plan Trust Fund
Healthcare of Ontario Pension Plan Trust Fund significantly reduced its stake in Innoviva, Inc. (NASDAQ:INVA) by 79.4% in the first quarter, selling over 262,000 shares. Despite this sell-off, institutional ownership remains high at 99.12%, with other investors increasing their positions. Analysts generally maintain a "Moderate Buy" rating for Innoviva, with an average price target of $36.20, even as the stock experienced a slight decline.
Innoviva, Inc. Revenue Breakdown – NASDAQ:INVA
Innoviva, Inc. (NASDAQ:INVA) generated a total revenue of $411.33 million USD last year. The Respiratory Products segment was its top-performing segment, contributing the entirety of this revenue. The largest geographical contribution to the company's revenue came from Great Britain.
THRX5561968 Bond Profile — Key Metrics
This article provides a bond profile for THRX5561968, an Innoviva, Inc. bond with a 2.125% coupon maturing on March 15, 2028. It details key facts such as the issue date, outstanding amount, face value, and a description of Innoviva, Inc. and its biopharmaceutical activities.
THRX5561968 Bond Coupon Profile — Rate & Payments
This article provides a coupon profile for the Innoviva, Inc. 2.125% 15-MAR-2028 bond (THRX5561968). It details the current coupon rate of 2.13% and highlights that the next interest payment is scheduled for September 15, 2026. The piece also mentions that more in-depth coupon data, including historical payouts and payment schedules, is available.
Vanguard Capital Management (INVA) reports 3.7M Innoviva shares in Schedule 13G
Vanguard Capital Management LLC, along with its affiliates, has filed a Schedule 13G, disclosing beneficial ownership of 3,704,185 shares of Innoviva Inc (INVA) common stock, which represents a 5.01% stake in the company. Vanguard reports sole voting power over 546,132 shares and sole dispositive power over all 3,704,185 shares. The shares are held for Vanguard-managed funds and accounts, with no single person having an interest exceeding 5% of the class.
Trading Systems Reacting to (INVA) Volatility
This article analyzes Innoviva Inc. (NASDAQ: INVA) volatility, highlighting divergent sentiment across all time horizons and elevated downside risk. AI models have generated three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also provides multi-timeframe signal strengths and support/resistance levels for the stock.
Innoviva Inc (INVA) Risk Assessment: Volatility, Financial Risk & Investment Risk
The article provides a risk assessment for Innoviva Inc (INVA), indicating a current risk assessment score of 7.78, ranking it 34 out of 155 in the Pharmaceuticals industry. The company's beta is 0.36, suggesting it tends to underperform in up markets but has smaller declines in down markets. It includes various metrics such as volatility, maximum drawdown, Sharpe Ratio, and liquidity.
Innoviva, Inc. Revenue Breakdown – BX:HVE
Innoviva, Inc. generated 326.09 million CHF in revenue last year, primarily from its Respiratory Products segment. The largest contribution to revenue came from Great Britain. The company's revenue from Respiratory Products was slightly higher than the previous year.
Innoviva Inc (INVA) Financial Health: Profitability & Balance Sheet Analysis
The article analyzes the financial health of Innoviva Inc (INVA), highlighting its robust status and high operating efficiency with a current financial score of 8.99. The company's latest quarterly revenue increased by 10.56% year-over-year, and net profit saw a significant increase of 500.56% year-over-year. Innoviva Inc ranks 19 out of 155 in the Pharmaceuticals industry, indicating strong performance despite some financial data not yet being disclosed.
INVA|Innoviva Inc|Price:21.500|Chg%:-0.310
This article provides a detailed company profile for Innoviva Inc (INVA), a diversified holding company with a portfolio of royalties and healthcare assets. It lists key financial data, company executives, and institutional shareholding information. Innoviva's product portfolio includes respiratory assets partnered with GSK, GIAPREZA, XERAVA, and XACDURO, with zoliflodacin in Phase III clinical trials.
Innoviva Inc (INVA) Valuation: PE, PB & Fair Value Analysis
Innoviva Inc (INVA) has a current valuation score of 8.20, ranking 102 out of 155 in the Pharmaceuticals industry. The company's P/E ratio stands at 2.92, which is significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not been disclosed by the company yet.
Innoviva Inc (INVA) Cash Flow
This article provides a detailed cash flow statement for Innoviva Inc (INVA), covering quarterly and annual data for operating, investing, and financing activities. It presents key financial metrics such as net income, operating gains/losses, deferred tax, and changes in working capital over several fiscal years. The content also offers explanations for different types of cash flow and their significance, along with recent figures for Innoviva's operating cash flow, capital expenditures, and free cash flow.
Innoviva, Inc. Revenue Breakdown – MUN:HVE
This article provides a revenue breakdown for Innoviva, Inc. (MUN:HVE), highlighting its financial performance from the previous year. The company generated 350.21 million EUR, with the Respiratory Products segment being the top performer. The United Kingdom was the largest contributor to the company's revenue.
Thai FDA approves Dr Reddy’s gonorrhoea antibiotic
The Thai Food and Drug Administration (FDA) has approved Nuzolvence (zoliflodacin), an oral antibiotic developed by Dr Reddy’s Laboratories for uncomplicated urogenital gonorrhoea. This approval marks a significant step in providing an innovative treatment, especially for multidrug-resistant strains, following a public-private R&D partnership with Innoviva Specialty Therapeutics and trial sponsorship by GARDP. Nuzolvence was initially approved by the US FDA earlier this year.
Innoviva, Inc. Revenue Breakdown – DUS:HVE
Innoviva, Inc. (DUS:HVE) generated 350.21 million EUR in revenue last year, primarily from its Respiratory Products segment. The largest contribution to revenue came from Great Britain, accounting for 201.34 million EUR. This financial overview details the company's top-performing segments and regional contributions.
INVA|Innoviva Inc|Price:21.440|Chg%:+0.240
Innoviva Inc (INVA) closed at $21.440, up 1.13%, with a market cap of $1.58 billion. The company has strong fundamentals, high growth potential, and is considered fairly valued by analysts, who largely rate it as a "Buy" with a target price of $35.50. Innoviva Inc is a diversified holding company focusing on healthcare assets, including respiratory royalties and various approved drugs, and analysts anticipate the stock price to remain stable in the medium term.
How Innoviva Inc. (INVA) Affects Rotational Strategy Timing
This article analyzes Innoviva Inc. (INVA) using AI models to determine its impact on rotational strategy timing. It highlights divergent sentiment, support/resistance levels, and presents three trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal strengths for near-term, mid-term, and long-term horizons, suggesting choppy conditions.
How Innoviva Inc. (INVA) Affects Rotational Strategy Timing
This article analyzes Innoviva Inc. (INVA) using AI models to provide trading strategies. It highlights a weak near-term sentiment for INVA but strong long-term prospects, with an exceptional risk-reward setup targeting an 8.4% gain against a 0.3% risk. The analysis includes position, momentum breakout, and risk hedging strategies, noting divergent sentiment across various time horizons.
How Innoviva Inc. (INVA) Affects Rotational Strategy Timing
This article analyzes Innoviva Inc. (INVA) with a focus on its impact on rotational strategy timing, highlighting weak near-term sentiment but long-term strength. It presents AI-generated trading strategies for different risk profiles, including position, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis. The analysis details support and resistance levels across near, mid, and long-term horizons for INVA.
Innoviva (INVA) Leaves Russell Indexes, Is The Stock Still Cheap?
Innoviva (INVA) has been removed from several Russell indexes, potentially leading to increased short-term trading. Despite mixed stock momentum (up 11.98% YTD but down quarterly), analysis suggests the stock is undervalued with a P/E of 3.3x, significantly below both internal fair value estimates and industry averages. However, concerns remain about its concentrated royalty portfolio and declining net income.
Enterprise value to EBITDA forward of Innoviva, Inc. – SWB:HVE
This article provides financial information for Innoviva, Inc. (SWB:HVE) focusing on its Enterprise Value to EBITDA forward. It is presented on the TradingView platform, which offers various financial tools and market data services.
Price to sales forward of Innoviva, Inc. – SWB:HVE
This page from TradingView provides a financial overview of Innoviva, Inc. (SWB:HVE) listed on the Stuttgart Stock Exchange, specifically focusing on its forward price-to-sales ratio. While the article highlights the financial metric, no specific values or analytical details are presented on this particular page. The rest of the content consists of navigation links and general platform information.
INVA - Innoviva Inc Latest SEC Filings
This article provides the latest SEC filings information for Innoviva Inc (INVA), alongside comprehensive financial data and performance metrics. It includes details on market capitalization, income, sales, dividend information, various financial ratios, share performance, and analyst recommendations. The data indicates Innoviva Inc's current financial health and market position.
Is Innoviva (INVA) Trading Index Membership for a Deeper Bet on Nortiva Bio’s LYNX Platform?
Innoviva (INVA) was recently delisted from several Russell growth indices, including the Russell 2000 and 3000 Growth benchmarks, coinciding with its strategic shift towards building Nortiva Bio and the LYNX long-acting oral drug delivery platform. This removal may impact liquidity and introduce short-term volatility, but doesn't alter core operations, pipeline, or buybacks. Investors now face weighing potential funding needs for Nortiva, reduced index presence, and forecast earnings pressure, although the company maintains a cash-generative royalty and anti-infectives business.
Is Innoviva (INVA) Trading Index Membership for a Deeper Bet on Nortiva Bio’s LYNX Platform?
Innoviva, Inc. (INVA) was recently removed from several Russell growth indices, including the Russell 2000 and 3000 Growth benchmarks, coinciding with its strategic shift to build Nortiva Bio around the LYNX drug delivery platform. This change may impact the company's trading liquidity and introduce short-term volatility, but its core operating drivers, pipeline progress, and buybacks remain unaffected. Investors should consider the potential funding needs for Nortiva and the effect of reduced index inclusion on sentiment, especially as earnings are forecast to soften, while evaluating the company's transition from a royalty business to a biopharmaceutical company focused on its new platform.
Is Innoviva (INVA) One of the Best Cheap Small Cap Stocks to Buy Now?
Innoviva, Inc. (NASDAQ: INVA) is highlighted as a potentially good small-cap stock due to its subsidiary Nortiva Bio, Inc. launching as a clinical-stage biopharmaceutical company. Nortiva Bio will focus on developing long-acting oral medicines using Innoviva's proprietary LYNX™ drug delivery platform, acquired in 2025. This platform aims to improve medication adherence and efficacy by transforming daily pills into single-dose, long-acting therapies.
5 Cheap Small Cap Stocks to Buy Now
This article lists
Is Innoviva (INVA) Undervalued After Nortiva Bio Launch And XACDURO Deal?
Innoviva (INVA) has gained attention after launching Nortiva Bio and signing a distribution deal for XACDURO, leading to positive year-to-date and one-month share price returns. Despite a low P/E ratio of 3.4x compared to industry averages and analysts' price targets, the company faces declining earnings forecasts. However, a high Return on Equity and a Discounted Cash Flow (DCF) analysis suggest the stock is significantly undervalued, trading at a 59.1% discount to its estimated future cash flow value.
Innoviva, Inc.(NasdaqGS: INVA) dropped from Russell Small Cap Comp Growth Benchmark
Innoviva, Inc. (NasdaqGS: INVA) has been removed from the Russell Small Cap Comp Growth Benchmark. This news comes amidst recent corporate activities for Innoviva, including an acquisition of the LYNX platform and a licensing deal, as well as several earnings reports and board changes. The company, a diversified holding company with a focus on healthcare assets and royalties, was trading at $23.14 USD, down 1.82%.
Innoviva, Inc.(NasdaqGS: INVA) dropped from Russell 3000 Growth Benchmark
Innoviva, Inc. (NasdaqGS: INVA) has been removed from the Russell 3000 Growth Benchmark. The pharmaceutical company, which specializes in respiratory assets and other healthcare products, recently announced an acquisition and a licensing deal, amidst reporting its Q1 revenue.
How Investors Are Reacting To Innoviva (INVA) Expanding Drug Delivery Tech And XACDURO Global Partnership
Innoviva recently launched Nortiva Bio, a clinical-stage subsidiary focused on long-acting oral drug delivery, and partnered with Dr. Reddy's Laboratories for global distribution of XACDURO. These moves expand Innoviva's drug delivery technology exposure and global commercial footprint, but also introduce new clinical and execution risks alongside potential long-term upside. Investors are now weighing this richer R&D profile against the company's currently low earnings multiple and varying fair value estimates.
